Isavuconazole in the management of central nervous system fungal infections: Parenchymal penetration and clinical performance

Clicks: 14
ID: 339552
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #190 of 195 articles by views in medical mycology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 195 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Invasive fungal infections (IFIs) involving the central nervous system (CNS) represent a critical challenge, with mortality of 50% or more in cerebral aspergillosis, mucormycosis, fusariosis and cryptococcal meningitis, and pharmacokinetic (PK) access restricted by the blood-brain barrier (BBB). This review analyzes the clinical performance and parenchymal penetration of isavuconazole (ISA), a second-generation triazole. ISA exhibits linear PK, a cyclodextrin-free intravenous formulation, and high tissue affinity, favored by moderate lipophilicity (experimental logP 2.56) and in vitro inhibition of P-glycoprotein and breast cancer resistance protein (BCRP) efflux transporters. Experimental evidence from animal models shows brain-to-plasma ratios of 0.42 to 1.8, indicating efficient BBB crossing. Human biopsy data show a fundamental PK dichotomy. While cerebrospinal fluid concentrations are restricted (about 1% of plasma), levels in fungal abscesses and inflamed parenchyma reach up to 5.11 mg/L, exceeding the minimum inhibitory concentration reported for Aspergillus fumigatus in those cases. Clinically, ISA was associated with a response in 70% of first-line (n = 10) and 73% of salvage-treated patients (n = 30) with cerebral aspergillosis, and 82% of 28 patients with CNS-only coccidioidomycosis improved or stabilized. Meta-analyses suggest fewer drug-related adverse events and, in randomized subgroups, fewer hepatobiliary events compared with voriconazole, although moderate cytochrome P450 3A4 inhibition warrants monitoring of calcineurin and mechanistic target of rapamycin (mTOR) inhibitors in transplant recipients. ISA is a strategic option for high-complexity CNS-involving IFIs, serving as a therapeutic alternative in salvage and prolonged-maintenance settings, though first-line use in CNS infection awaits confirmation from randomized trials.
Reference Key
openalex_W7225751602 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal medical mycology
Year 2026
DOI
10.1093/mmy/myag122
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.